Preparation of Alginate Nanoparticles Using Eudragit E100 as a New Complexing Agent: Development, &lt;I&gt;In-Vitro&lt;/I&gt;, and &lt;I&gt;In-Vivo&lt;/I&gt; Evaluation

Sonavane, Ganeshchandra S.; Devarajan, Padma V.

doi:10.1166/jbn.2007.005

Cited by 21 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimized particles displayed a high encapsulation efficiency (82%), high drug loading (49%), and a particle size of 525 nm (39). In addition, a pharmacokinetic study in rabbits revealed better bioavailability of gliclazide with sustained release in plasma from gliclazide NPs compared to plain gliclazide.…”

Section: Alginatesmentioning

confidence: 98%

“…A critical adjustment in the relative concentrations of alginate and the cation results in a pregel state, i.e., alginate NPs. Composite NPs are obtained by adding a small volume of the aqueous solution of the second polymer (chitosan or cationic polymethacrylates) to the initial alginate aqueous solution with calcium chloride (37,39).…”

Section: Alginatesmentioning

confidence: 99%

“…Hydrophilic drugs (e.g., rifampicin and gliclazide) are generally efficiently entrapped in NPs made of alginate, which is usually blended with another polymer, and display an enhanced oral bioavailability and biological performance, as supported by several studies (39,41). Ahmad and coworkers reported high encapsulation efficiency of antituberculosis drugs in alginate-chitosan NPs ranging from 80-90% for rifampicin, 88-95% for ethambutol, and 70-90% for isoniazid/pyrazinamide (41).…”

Section: Alginatesmentioning

confidence: 99%

See 2 more Smart Citations

Engineered Nanoparticulate Drug Delivery Systems: The Next Frontier for Oral Administration?

Diab

Jaafar‐Maalej

Fessi

et al. 2012

AAPS J

View full text Add to dashboard Cite

Abstract. For the past few decades, there has been a considerable research interest in the area of oral drug delivery using nanoparticle (NP) delivery systems as carriers. Oral NPs have been used as a physical approach to improve the solubility and the stability of active pharmaceutical ingredients (APIs) in the gastrointestinal juices, to enhance the intestinal permeability of drugs, to sustain and to control the release of encapsulated APIs allowing the dosing frequency to be reduced, and finally, to achieve both local and systemic drug targeting. Numerous materials have been used in the formulation of oral NPs leading to different nanoparticulate platforms. In this paper, we review various aspects of the formulation and the characterization of polymeric, lipid, and inorganic NPs. Special attention will be dedicated to their performance in the oral delivery of drug molecules and therapeutic genes.

show abstract

Section: Alginatesmentioning

confidence: 98%

Section: Alginatesmentioning

confidence: 99%

Section: Alginatesmentioning

confidence: 99%

See 1 more Smart Citation

Engineered Nanoparticulate Drug Delivery Systems: The Next Frontier for Oral Administration?

Diab

Jaafar‐Maalej

Fessi

et al. 2012

AAPS J

View full text Add to dashboard Cite

show abstract

“…Acrylate derivatives: Eudragit E-100, Eudragit ® E PO and polymethacrylate Microparticles, nanoparticles, beads, tablets [100][101][102] The acrylate derivative may be introduced in alginate core or as coat to alginate matrix through the formation of inter-polyelectrolyte complex.…”

Section: +mentioning

confidence: 99%

Alginate graft copolymers and alginate–co-excipient physical mixture in oral drug delivery

Wong

2011

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Use of alginate graft copolymers in oral drug delivery reduces dosage form manufacture complexity with reference to mixing or coating processes. It is deemed to give constant or approximately steady weight ratio of alginate to covalently attached co-excipient in copolymers, thereby leading to controllable matrix processing and drug release. This review describes various grafting approaches and their outcome on oral drug release behaviour of alginate graft copolymeric matrices. It examines drug release modulation mechanism of alginate graft copolymers against that of co-excipients in non-grafted formulations. Key findings Drug release from alginate matrices can be modulated through using either co-excipients or graft copolymers via changing their swelling, erosion, hydrophobicity/ hydrophilicity, porosity and/or drug adsorption capacity. However, it is not known if the drug delivery performance of formulations prepared using alginate graft copolymers is superior to those incorporating graft-equivalent co-excipient physically in a dosage form without grafting but at the corresponding graft weight, owing to limited studies being available. Conclusions The value of alginate graft copolymers as the potential alternative to alginate-co-excipient physical mixture in oral drug delivery cannot be entirely defined by past and present research. Such an issue is complicated by the lack of green chemistry graft copolymer synthesis approach, high grafting process cost, complications and hazards, and the formed graft copolymers having unknown toxicity. Future research will need to address these matters to achieve a widespread commercialization and industrial application of alginate graft copolymers in oral drug delivery

show abstract

“…22 In particular, mixing cationic and anionic polymers in order to form interpolyelectrolyte complexes (IPEC) including those involving countercharged Eudragit types copolymers, were examined in several reviews 23,24 and seems to be an interesting strategy of encapsulation purposes in order to control to control NSAIDs release. The literature was focused essentially on tablet formulations based on IPEC between sodium alginate (anionic) and the cationic Eudragit EPO 22,25,26 or Eudragit RL 27 ; and between chitosan (cationic) with different types of anionic Eudragits. 28,29 Production of large sized beads of chitosan/succinic acid/Eudragit RS/RL was also carried out.…”

Section: Introductionmentioning

confidence: 99%

Ultrasonic atomization and polyelectrolyte complexation to produce gastroresistant shell–core microparticles

Dalmoro

Sitenkov

Lamberti

et al. 2015

J of Applied Polymer Sci

View full text Add to dashboard Cite

In this study ultrasound-assisted atomization technique was combined with two-stages polyelectrolyte complexation to produce enteric shell-core microparticles encapsulating a non-steroidal, anti-inflammatory gastrolesive active ingredient indomethacin. In particular, a solution of the anionic biopolymer alginate, containing indomethacin, was sprayed in fine droplets which were complexed with a cationic (meth)acrylate copolymer, Eudragit V R E 100, which, in turn, was complexed by the anionic copolymer Eudragit V R L30D-55. The first complexation stage was applied to achieve a high drug encapsulation efficiency; the second one to assure good gastroresistance feature. The novel protocol has been found more effective in terms of loading, encapsulation efficiency, and enteric properties during in vitro release tests, than conventional procedures which involved alginate cross-linking by charged ions. Furthermore ultrasonic atomization-polyelectrolytes complexation preparation approach was performed using mild conditions, aqueous solutions, in the absence of organic solvents and chemical cross-linkers.

show abstract

Preparation of Alginate Nanoparticles Using Eudragit E100 as a New Complexing Agent: Development, <I>In-Vitro</I>, and <I>In-Vivo</I> Evaluation

Cited by 21 publications

References 0 publications

Engineered Nanoparticulate Drug Delivery Systems: The Next Frontier for Oral Administration?

Engineered Nanoparticulate Drug Delivery Systems: The Next Frontier for Oral Administration?

Alginate graft copolymers and alginate–co-excipient physical mixture in oral drug delivery

Ultrasonic atomization and polyelectrolyte complexation to produce gastroresistant shell–core microparticles

Contact Info

Product

Resources

About